IMCB works closely with industrial, translational clinical and academic partners both in Singapore and worldwide. Over the years, many successful collaborations have been fostered between IMCB and its partners even leading to the conception of joint-laboratories with some of our partners.
Joint-laboratories at IMCB
| 1) Asia Biotech Pte Ltd - IMCB Joint Lab | Research on novel antibodies and chimeric proteins for cancer therapy
  |
2) Tessa Therapeutics Pts Ltd - IMCB Joint Lab
| Immuno-oncology laboratory using Tessa's core Virus Specific T cell (VST) platform to create the next generation of immunotherapies to treat solid tumors
 |
| 3) Lion TCR Pte Ltd - IMCB joint lab | |
Strategic Alliances
Singapore Eye Research Institute (SERI) - IMCB
The SERI-IMCB Program in Retinal Angiogenic Diseases (SIPRAD) focuses on discovery research as well as translational and clinical research in developmental angiogenesis, neovasculature in eye diseases and new drug targets and drug repurposing |  |
Academic and clinical collaborations
IMCB's researchers work closely with clinicians and scientists across Singapore in search of answers in burning areas of research and closely complement each other's expertise. We have collaborations with various local hospitals and universities various areas of research which include, but are not limited to cancer research, infectious diseases, autoimmunity and immunology, biomarker discovery, neuroscience and genetics.
IMCB's academic institution partners include:
- National University Hospital
- Tan Tock Seng Hospital
- Singapore General Hospital
- KKH Hospital
- National Cancer Centre of Singapore
- Singapore Eye Research Institute
- National Skin Centre
- National Neuroscience Institute
- National Heart Centre
- DUKE-NUS
- National University of Singapore
- Nanyang Technological University
Here at IMCB, we believe in bringing together the best expertise globally. We have also established collaborations with various research institutes and universities around the world, including RIKEN, University of South Australia, and the Centenary Institute of Cancer Medicine and Cell Biology.
Industry partners
IMCB works closely with international renown pharmaceutical companies, medical device and consumer care companies. Various models of partnership include collaboration models and fee-for-service agreements. Our present partners include Becton Dickinson, MSD, Ipsen Biopharm Ltd, Procter & Gamble (P&G), Denka Company Limited, AB Sciex, Cordlife Group and Histoindex Pte Ltd.
Human skin research has attracted significant recent investment in Singapore. Multi-lab IMCB partnerships are ongoing with P&G in hair quality and skin barrier function. Separately, IMCB has carried out large-scale RNA interference screens to understand how skin constituents are regulated and collaborated with P&G on hair follicle-associated immune cells and their contribution to hair health. Other collaborative efforts have led to licensing of zebrafish (Danio rerio) genetic markers, microbial collections for drug screening, development of SARS and malaria diagnostic kits, and the licensing of several monoclonal antibodies. Research on induced pluripotent stem cell in collaboration with Cordlife is also ongoing to develop chemically-induced iPS cells using banked cord blood.
IMCB's patience and persistence has paid off, where an investment made in 1993 led to the IMCB spin-off MerLion Pharmaceuticals successfully carrying out Phase II clinical trials in 2014 for urinary tract infection using Finafloxacin, which was then approved in February 2015 by the FDA. Finafloxacin has also been approved by the FDA for the treatment of "swimmer's ear", acute otitis externa.
Work with us
IMCB is open to discussions on collaborations based on common scientific interest and partnerships that further enhance and complement each other's expertise. Various collaboration models are open for discussion.